Determining patient preferences for improved chemotoxicity during treatment for advanced bladder cancer.
Determining patient preferences for improved chemotoxicity during treatment for advanced bladder cancer Conventional treatment for advanced bladder cancer is methotrexate, vinblastine, doxorubicin plus cisplatin (MVAC), with a median survival of 1 year but significant toxicity. The newer combination of gemcitabine plus cisplatin (GC) has demonstrated comparable survival and an improved toxicity profile (Von der Maase et al. 2000). At present, the importance to patients of the toxicity of chemotherapy has not been widely studied. An earlier study in bladder cancer indicated that toxicity was an important determinant of treatment preference (Davey et al. 2000). A study of preferences for advanced bladder cancer therapy in the UK was proposed.
Aristides
M
M
M-TAG Limited, London, UK.
Von Der Maase
H
H
Roberts
T
T
Brown
A
A
Kielhorn
A
A
Bhalla
S
S
D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D002945:Cisplatin / Q000009:adverse effects; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives*; D004317:Doxorubicin / Q000009:adverse effects; D006801:Humans; D008727:Methotrexate / Q000009:adverse effects; D017060:Patient Satisfaction; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000523:psychology; D014747:Vinblastine / Q000009:adverse effects; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D003841:Deoxycytidine; D014747:Vinblastine; D004317:Doxorubicin; D002945:Cisplatin; D008727:Methotrexate; D000093542:Gemcitabine